An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Trial Profile

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 07 Aug 2017 According to a Kura Oncology media release, two confirmed partial responses were observed in three patients with HRAS mutant SCCHN from eleven evaluable patient in the first stage due to this a protocol amended to enroll additional sevan patients in the second stage
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 15 May 2017 Data from this trial will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017, according to a Kura Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top